For patients with germlineBRCA mutations and previously treated HER2-negative, advancedbreast cancer (either hormone receptor positive or triple negative), the oralinhibitors of PARP olaparib and talazoparib have shown efficacy.3 Here, NR4A1 is linked to cancer.